Patient Rating:

4.8 out of 5

59 Patient Ratings
10 Patient Comments

John Sweetenham, M.D., FACP, FRCP

Patient Rating:

4.8 out of 5

59 Patient Ratings
10 Patient Comments

Specialties

Languages

  • English

Clinical Details

Schedule An Appointment Clinical Office Address
(801) 585-6906 Huntsman Cancer Hospital
Clinic 2C/BMT, Hematology-Malignant
1950 Circle of Hope
Salt Lake City, UT 84112
Map

Bio

John Sweetenham, MD, FRCP, FACP, is a practicing hematologist whose central clinical research interest is lymphoma and the use of stem cell transplantation. He is internationally renowned for his clinical research and has authored more than 200 original articles, chapters, and books in this area of investigation. He has been principal investigator on national and international trials in lymphoma, and is a former core committee member of the Eastern Cooperative Oncology Group Lymphoma Committee and ECOG national principal investigator for studies in Hodgkin lymphoma. He also serves as Chairman of the Clinical Trials Committee of Leukemia and Lymphoma Research, UK.

Dr. Sweetenham has been listed in “Best Doctors in America” every year since 2003, Castle Connoly’s “America’s Top Doctors,” and “America’s Top Doctors for Cancer” every year since 2009, and has recently been acknowledged by “US News Top Doctors” and Angie’s List for Healthcare.

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor (Clinical)
Academic Divisions Hematology/BMT
Board Certification National Board of Medical Examiners
Cancer Center Programs Experimental Therapeutics

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Likelihood of recommending care provider
4.9
My confidence in care provider
4.9
Time care provider spent with me
4.8
Care provider spoke using clear language
4.9
Care provider's effort to include me in decisions
4.8
Care provider's concern for questions & worries
4.8
Care provider's explanation of condition/problem
4.9
Wait time at clinic
4.3
Care provider's friendliness and courtesy
4.9

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

February 07, 2015

Excellent information provided, excellent processing of blood draw and most excellent with follow up appointments. Addressed my complaint about parking and made arrangements for care at another clinic.

July 22, 2014

As always I am impressed with the level of care I am receiving.

February 27, 2014

EVERYTHING GREAT

February 01, 2014

I had many questions which were answered for me by Dr Sweetenham

January 10, 2014

Type of chemo drugs, potential side effects, ancillary medications, etc., not really discussed.

November 30, 2013

Dr Sweetenham is wonderful to listen to us and make us feel like he has plenty of time for us!!! This is very important to us at this difficult time of having a loved one have cancer. Dr Sweetenham always makes sure he has answered all of our questions and concerns also. He is very knowledable and keeps us informed of the latest studies, info, etc...

November 11, 2013

I came to Huntsman for a second opinion but I was very impressed with the care that I will continue to be followed there.

September 25, 2013

Dr. Sweetenham speaks calmly, explains options, and most importantly gives me confidence that I'm going to be okay.

August 19, 2013

dr sweedenam was great

August 06, 2013

Bedside manner of Dr Sweetanen was amazing!

Academic Profile

Research Interests

  • Stem Cell Transplantation
  • Lymphomas

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor (Clinical)
Academic Divisions Hematology/BMT
Board Certification National Board of Medical Examiners
Cancer Center Programs Experimental Therapeutics

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 213-5636 Huntsman Cancer Institute
Hematology and Hematologic Malignancies
2000 Circle of Hope
Salt Lake City, UT 84112

Academic Bio

John Sweetenham, MD, FRCP, FACP, is executive medical director and senior director of clinical affairs at Huntsman Cancer Institute. He is also a professor of medicine in the Department of Hematology at the University of Utah and a member of the Experimental Therapeutics Program.

Dr. Sweetenham's clinical research focus is on malignant lymphomas and the use of stem cell transplantation. He has been principal investigator on national and international trials in lymphoma and is currently a core committee member of the Eastern Cooperative Oncology Group Lymphoma Committee and ECOG national principal investigator for studies in Hodgkin lymphoma. He serves as chairman of the Clinical Trials Committee of Leukemia and Lymphoma Research, UK.

Dr. Sweetenham attended medical school at St. Bartholomew's Hospital in London, UK, and trained in oncology at the University of Southampton, UK. He has served as director of the Hematologic Malignancies and Blood and Marrow Transplant Programs at the University of Colorado; associate director for clinical research at the University of Arizona; vice chairman for clinical research at the Cleveland Clinic Taussig Cancer Institute and professor of medicine at the Cleveland Clinic Lerner College of Medicine; and medical director of the UCSD Nevada Cancer Institute.

Education

Education History

Type School Degree
Fellowship Harvard Medical School
Tumor Immunology
Visiting Fellow
Fellowship CRC Wessex Medical Oncology Unit
Oncology
Fellow
Doctoral Training University of Southampton
Medicine
Ph.D.
Research Fellow University of Southampton
Oncology
Research Fellow
Professional Medical The Medical College of St Bartholomew's Hospital
M.B.B.S.
Undergraduate St Bartholomew's Hospital Medical College, University of London
Biochemistry
B.Sc.

Publications

Selected Provider Publications

Journal Article

  1. Portell CA, Aronow ME, Rybicki LA, Macklis R, Singh AD, Sweetenham JW (2014). Clinical characteristics of 95 patients with ocular adnexal and uveal lymphoma: treatment outcomes in extranodal marginal zone subtype. Clin Lymphoma Myeloma Leuk, 14(3), 203-10.
  2. Lazaryan A, Hussein MA, Reu FJ, Faiman B, Habecker B, Ann Karam M, Reed J, Hamilton K, Waksman J, Bruening K, Srkalovic G, Andresen S, Kalaycio M, Sweetenham JW, Sobecks R, Dean R, Knight R, Zeldis JB, Baz R (2014). Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. Am J Hematol, 89(4), 349-54.
  3. Aronow ME, Portell CA, Sweetenham JW, Singh AD (2014). Uveal lymphoma: clinical features, diagnostic studies, treatment selection, and outcomes. Ophthalmology, 121(1), 334-41.
  4. Aranow ME, Portell CA, Rybicki LA, Sweetenham JW, Singh AD (2013). Ocular Adnexal Lymphoma: Assessment of a TNM Staging System [Epub ahead of print]. Ophthalmology, epub ahead.
  5. Aronow ME, Portell CA, Rybicki LA, Sweetenham JW, Singh AD (2013). Ocular adnexal lymphoma: assessment of a tumor-node-metastasis staging system. Ophthalmology, 120(9), 1915-9.
  6. Deauna-Limayo D, Rajabi B, Qiu W, Htut M, Sweetenham J (2013). LETTER TO THE EDITOR: Kaposi's Sarcoma After Non-Myeloablative Hematopoietic Stem Cell Transplant: Response to Withdrawal of Immunosuppressant Therapy Correlated with Whole Blood Human Herpes Virus-8 RT-PCR levels. (Epub ahead of print) Leuk Lymphoma.
  7. Waterman J, Rybicki L, Bolwell B, Copelan E, Pohlman B, Sweetenham J, Dean R, Sobecks R, Andresen S, Kalaycio M (2012). Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. Bone Marrow Transplant, 47(4), 488-93.
  8. Mahindra A, Bolwell BJ, Rybicki L, Elder P, Kalaycio M, Dean R, Avalos B, Sobecks R, Tench S, Andresen S, Pohlman B, Sweetenham J, Devine S, Copelan E (2012). Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia. Bone Marrow Transplant, 47(2), 231-5.
  9. Sweetenham JW (2012). How to treat patients with borderline DLBCL and Burkitt lymphoma. (Education Program of the European Hematology Association). Haematologica, 75-81.
  10. Malik S, Bolwell B, Rybicki L, Copelan O, Duong H, Dean R, Sobecks R, Kalaycio M, Sweetenham J, Pohlman B, Andresen S, Tench S, Koo A, Figueroa P, Copelan E (2011). Apheresis days required for harvesting CD34+ cells predicts hematopoietic recovery and survival following autologous transplantation. Bone Marrow Transplant, 46(12), 1519-25.
  11. Sweetenham JW (2011). "Pet negativity"--the new goal of cytoreductive therapy in Hodgkin's lymphoma? Biol Blood Marrow Transplant, 17(11), 1569-70.
  12. Sweetenham JW, Polliack A (2011). Progressive transformation of germinal centers and Hodgkin lymphoma: more insights but maybe more confusion? Leuk Lymphoma, 52(11), 2041-2.
  13. Sproat L, Bolwell B, Rybicki L, Dean R, Sobecks R, Pohlman B, Andresen S, Sweetenham J, Copelan E, Kalaycio M (2011). Vitamin D level after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant, 17(7), 1079-83.

Review

  1. Portell CA, Sweetenham JW (2012). Adult lymphoblastic lymphoma. [Review]. Cancer J, 18(5), 432-8.
  2. Hill BT, Sweetenham J (2012). Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma. [Review]. Leuk Lymphoma, 53(5), 763-9.

Book Chapter

  1. Sweetenham JW (In Press). Hodgkin’s Disease. In Cassidy J, Bisset D, Leng M, Wagstaff J (Ed.), The Oxford Handbook of Oncology. Oxford University Press.

Clinical Trials

Video & News